News
PCS12852 Improves Gastric Emptying in Gastroparesis Patients
Processa Pharmaceuticals announced that positive gastric emptying results from its PCS12852 Phase 2A Proof-of-Concept trial in patients with moderate to severe gastroparesis. PCS12852 is a
Yuhan’s ‘Lazertinib’ Phase 3 topline data shows ‘PFS Improvement’ as first line of therapy
On 14 October, Yuhan announced top-line Phase 3 study data of Lazertinib as 1st line treatment that has significantly improved progression-free survival (PFS) as the
[Job Opening] Business Development Manager – Boston office
[채용 공고]유한양행 미국 법인 – 유한 USA Position:Business Development Manager Work location:Boston, MA Responsibilities:1.개방형 기술혁신 및 In/Out Licensing Partnering 사업개발2.유망 바이오 기업 발굴 및 전략적
Yuhan Corporation to create a state-of-the-art R&D cluster in Gunpo-City, South Korea
Yuhan Corporation is working together with Gunpo City, South Korea to create a high-tech bio research base and CMC center in the industrial area of
Yuhan Corporation’s licensed-out non-alcoholic steatohepatitis drug to start phase 1 clinical trial in Europe
Expected to receive 10 million USD as a milestone payment Yuhan Corporation (000100. KS) announced on the 17th of November that the new drug candidate
Yuhan Corporation to invest 1.6 billion Won (1.34 million USD) in Yuhan USA U.S. Open Innovation Investment Continues
Yuhan USA strengthens its role as a ‘venture capital’. They purchased 750,000 shares of Processa Pharmaceuticals this year. Yuhan Corporation is spurring overseas open innovation expansion and strengthening